Our previous work, carried out in this same set of RA patients and at the same time, demonstrated allogeneic BM-MSCs also impair Th1 and Th17 cells, among others CD4+ and CD8+ T cell subsets, inhibiting the production of proinflammatory cytokines, while increasing IL-10 and TGF-β mRNA expression [21]. The gene discussed is CD4; the disease is rheumatoid arthritis.